Aethlon Medical, Inc. (AEMD)
NASDAQ: AEMD · Real-Time Price · USD
0.388
-0.012 (-2.98%)
At close: Oct 31, 2024, 4:00 PM
0.393
+0.005 (1.29%)
After-hours: Oct 31, 2024, 6:25 PM EDT
Company Description
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States.
It develops Hemopurifier, a clinical-stage immunotherapeutic device for cancer and life-threatening viral infections and use in organ transplantation.
The company was founded in 1984 and is based in San Diego, California.
Aethlon Medical, Inc.
Country | United States |
Founded | 1984 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 14 |
CEO | James Frakes |
Contact Details
Address: 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 United States | |
Phone | 619 941 0360 |
Website | aethlonmedical.com |
Stock Details
Ticker Symbol | AEMD |
Exchange | NASDAQ |
Fiscal Year | April - March |
Reporting Currency | USD |
CIK Code | 0000882291 |
CUSIP Number | 00808Y307 |
ISIN Number | US00808Y4061 |
Employer ID | 13-3632859 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
James B. Frakes M.B.A. | Chief Executive Officer, Chief Financial Officer, Secretary and Director |
Guy F. Cipriani BS (Eng.), MBA | Senior Vice President and Chief Operating Officer |
Dr. Steven P. LaRosa M.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 3, 2024 | 8-K | Current Report |
Oct 2, 2024 | 8-K | Current Report |
Sep 19, 2024 | 8-K | Current Report |
Aug 15, 2024 | ARS | Filing |
Aug 15, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Aug 15, 2024 | DEF 14A | Other definitive proxy statements |
Aug 15, 2024 | 10-K/A | [Amend] Annual report |
Aug 14, 2024 | 10-Q | Quarterly Report |
Aug 14, 2024 | 8-K | Current Report |
Aug 12, 2024 | 8-K | Current Report |